Evommune stock
EVMNNYSEEvommune, Inc., HealthcareISIN US30054Y1073
33Score 33 out of 100, Weak
Price and trend
43 / 100
Price history
−59% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 53% below it.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 75% below its 52-week high. Largest decline in 1 year: 84% (February 2026 to October 2026).
Chart figures for advanced users
- SMA 50$7.65
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.22
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.10
- The lowest closing price of the last twelve months.
- Resistance$31.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Evommune, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $291.06M, is number 290 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $13M (up 85.7% year on year) and a loss of $68.87M.
- For fiscal 2026, analysts expect on average revenue of $3.13M (down 76%) and adjusted earnings per share of −$3.48.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 659 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $200.79M, financial debt $8.11M.Stability 69
Weaknesses
- Volatile share priceVolatility 120% a year over the last 12 months.Stability 69
- Loss-makingLoss of $94.67M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 59% over the last 12 months.Momentum 31
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 0.2). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 85.7% on the prior year. Revenue has grown strongly since 2023, at around 61% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −624%, net −530%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported −$0.85 (expected −$0.82)below expectations
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $146,260 in total. 3 insiders sold, $654,997 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Evommune
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Turn TherapeuticsTTRX $320.99M45
- MapLight TherapeuticsMPLT $318.78M33
- Vicore Pharma HoldingVICO.ST $318.18M38
- Kyverna TherapeuticsKYTX $316.64M28
- Cabaletta BioCABA $312.79M28
- Allogene TherapeuticsALLO $311.85M27
- Valerio TherapeuticsALVIO.PA $309.27M40
- Nautilus BiotechnolgyNAUT $308.24M40
ETFs that hold Evommune
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.